Key Stats for AbbVie Stock
- Current Price: $263.04
- Target Price (Mid): ~$361
- Street Target: ~$279
- Potential Total Return: ~37% (over ~4.3 years, to year-end 2030)
- Annualized IRR: ~8% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
AbbVie (ABBV) is priced as an immunology story: Skyrizi and Rinvoq grew fast enough to cover the HUMIRA patent cliff, and the stock has re-rated toward its 52-week high near $267 to reflect it. Oncology already runs at a multi-billion-dollar clip on Venclexta and newer launches, yet the Street still models it as a rounding error next to immunology. At the September 15 Morgan Stanley fireside, management kept pointing to there as the next decade’s growth, and the reason arrived on September 3.
A 74% Response Rate That Beat Standard Therapy by Nearly 30 Points
On September 3, AbbVie reported Phase 3 CERVINO results for etentamig, a BCMA-directed T-cell engager, in patients with relapsed or refractory multiple myeloma who had already exhausted a median of three prior lines of treatment. The full topline results showed an objective response rate of 74.0% against 45.7% for standard therapy, and a 60% reduction in the risk of disease progression or death (hazard ratio 0.40). Those are large margins for a heavily pretreated population that had run out of good options.
The three approved BCMA bispecifics, Johnson & Johnson’s Tecvayli, Pfizer’s Elrexfio, and Regeneron’s Lynozyfic, all require weekly dosing with several early step-up doses. Etentamig uses a single step-up dose, then once-monthly dosing. On safety, R&D chief Roopal Thakkar said grade 3-plus infections ran under 30% versus “40-plus percent” for current molecules, with total cytokine release syndrome in the “60% to 70%” range for competitors against under 30% for etentamig. Monthly dosing plus a cleaner safety profile is what lets a community oncologist treat myeloma outside an academic center, which is why CEO Robert Michael called the community-setting opportunity “tremendous.” Etentamig is not yet approved: AbbVie plans to file with regulators this year, and full data land at the International Myeloma Society plenary in Glasgow on September 25.
See historical and forward estimates for AbbVie stock (It’s free!) >>>
The Pattern Behind the Readout: Buying the Decade After Immunology Peaks
Etentamig is the sharpest example of a wider strategy management reinforced on stage. The same day the myeloma data dropped, AbbVie closed its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart, a late-stage IL-13 antibody for atopic dermatitis, plus an IL-13/TSLP combination aimed at asthma. Chief Commercial Officer Jeff Stewart argued that the atopic dermatitis market holds roughly three times the moderate-to-severe patients of the psoriatic market, yet is less than one-third penetrated, and management used the phrase “mega blockbuster” in the announcement. The deal dilutes adjusted EPS by about $0.14 this year and $0.46 in 2027 before turning accretive in 2032, so it is a bet on the decade after immunology peaks, not the current quarter. The pattern showed up again on September 10, when AbbVie reported positive Phase 3 LUNA results for atogepant in menstrual migraine, a setting where no drug has ever won approval, extending a franchise the company already leads.
AbbVie carries an LTM gross margin near 73% and a return on invested capital of 34%, with net leverage down to 2.06x net debt to EBITDA. Q2 2026, reported July 31, delivered $16.99 billion in revenue, up 10.16% year over year, with adjusted EPS of $3.65, beating the Street’s $3.61.
Where the Premium Sits Against the Peer Group
On EV/EBITDA, AbbVie trades at 15.2x next-twelve-months against roughly 11.0x at Amgen, and its NTM P/E of 17.3x sits above the 16.0x at both Amgen and Gilead. That premium looks stretched for a company guiding to mid-single-digit long-term revenue growth. The justification is durability: Amgen and Gilead carry heavier near-term patent questions of their own, while AbbVie has already replaced an $18 billion HUMIRA hole and grown through it. Whether the premium holds depends on the pipeline converting, which is why readouts like CERVINO move the multiple and not just the headlines.
See how AbbVie performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $263.04
- Target Price (Mid): ~$361
- Potential Total Return: ~37%
- Annualized IRR: ~8% / year
See analysts’ growth forecasts and price targets for AbbVie stock (It’s free!) >>>
TIKR’s mid case values ABBV at about $361 per share, realized at year-end 2030, a total return near 37% and roughly 8% a year. We use the mid case because it holds the multiple roughly flat and lets the operating story carry the return, which fits a company whose re-rating has already largely happened.
- Revenue drivers: the immunology base, where Skyrizi and Rinvoq keep gaining share in underpenetrated markets like atopic dermatitis and IBD; and the newer franchises, where etentamig and the Apogee respiratory pipeline add revenue consensus barely credits.
- Margin driver: operating leverage, with net income margin widening toward roughly 42% as acquired IPR&D charges normalize.
- Primary risk: immunology erosion arriving faster than the new franchises scale, compressing the growth rate and the multiple at once.
- Upside: about $520 if margins reach 44% and the pipeline converts across oncology and respiratory.
- Downside: near $352 even on low-case assumptions, with the dividend and immunology base putting a floor under the return.
Conclusion
Full CERVINO data reach the International Myeloma Society plenary on September 25, and the market will read the detailed safety numbers against the three approved rivals. A clean profile that confirms the topline, monthly dosing and infection and CRS rates holding below the class, backs the community-setting thesis and supports a regulatory filing before year-end. A softer safety story, or a filing that slips into 2027, would say the oncology leg is further out than the stock now assumes.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in AbbVie?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
